Biliary Atresia — Clinician Review (with MMP‑7)

Definition

Biliary atresia (BA) is a progressive fibro‑obliterative cholangiopathy of the extrahepatic biliary tree present in infancy that causes obstructive conjugated hyperbilirubinemia and rapid progression to biliary cirrhosis if not treated.

Epidemiology

Incidence varies by region: approximately 1 in 5,000 to 1 in 20,000 live births (commonly quoted ~1:10,000–15,000), with geographic variation and higher rates in some Asian populations.
Most cases present in early infancy; >90% of symptomatic cases are identified within the first 2 months of life.
A minority of cases are associated with congenital syndromes (eg, biliary atresia with splenic malformation [BASM]) or genetic predisposition.

Pathogenesis and classification

Heterogeneous etiology: perinatal inflammatory/immune‑mediated injury, embryonic developmental anomalies, viral/environmental triggers, and genetic susceptibility in a subset.
Clinical patterns: perinatal (most common) and embryonic/fetal (often with associated anomalies such as laterality defects).
Pathology: obliteration/discontinuity of extrahepatic ducts, ductular reaction, bile plugs, portal inflammation, and rapidly progressive portal fibrosis.

Clinical presentation and age of onset

Typical age at presentation: signs usually become apparent between 2 and 8 weeks of age; persistent jaundice beyond 2 weeks warrants evaluation.
Cardinal features: conjugated hyperbilirubinemia, jaundice, pale (acholic) stools, dark urine, hepatomegaly, and failure to thrive.
Inspect for associated anomalies (cardiac, laterality, intestinal malrotation) that suggest embryonic BA/BASM.

Diagnostic evaluation (this shoud be done as part of a comprehensive evaluation of cholestatic jaundice in infants - see the guideline from NASPGHAN)

Rapid, structured evaluation is essential because earlier intervention improves outcomes.

Laboratory

Measure total and direct (conjugated) bilirubin; obtain AST, ALT, GGT, alkaline phosphatase, albumin, and coagulation studies (PT/INR).
Screen to exclude alternative causes: alpha‑1 antitrypsin level/phenotype, metabolic testing as indicated, infectious evaluation when appropriate.

Imaging

Abdominal ultrasound: assess gallbladder size/contractility and the triangular‑cord sign at the porta; absence or poorly defined gallbladder supports BA but is not diagnostic.
Hepatobiliary scintigraphy (HIDA/DISIDA) after phenobarbital priming per local protocol can show hepatic uptake with absent intestinal excretion, supporting obstructive cholestasis; interpret with caution early in illness.
Cross‑sectional imaging (MRI/CT) can add anatomic detail but does not replace cholangiography for definitive diagnosis.

Histology

Percutaneous liver biopsy commonly demonstrates ductular reaction/proliferation, portal inflammation, bile plugs in ductules/canaliculi, and variable portal fibrosis; biopsy is useful to support the diagnosis and exclude other causes.

Definitive diagnosis

Intraoperative cholangiography (diagnostic cholangiogram during surgical exploration) is the gold standard to confirm absence/obliteration of extrahepatic ducts and to distinguish BA from other obstructive lesions; performed when BA is strongly suspected.

MMP‑7 (matrix metalloproteinase‑7)

MMP‑7 (matrilysin) is a zinc‑dependent matrix metalloproteinase produced by epithelial cells that participates in extracellular matrix remodeling, epithelial injury responses, and fibrogenic signaling.
In BA, MMP‑7 expression is increased in bile duct epithelium and serum, reflecting biliary epithelial injury and fibroinflammatory activity.

MMP7 Summary

Diagnostic performance and evidence summary

Multiple studies and meta‑analyses report that serum MMP‑7 concentrations are substantially higher in infants with BA than in non‑BA neonatal cholestasis, with pooled sensitivity and specificity often reported in the high range (examples from major studies: sensitivity ≈90–95% and specificity ≈85–97% depending on cohort and cutoff).
Commonly cited single‑study cutoffs are in the range of ≈10 ng/mL (assay dependent) where discrimination between BA and other neonatal cholestasis is excellent in many cohorts, and combining MMP‑7 with GGT modestly improves diagnostic accuracy in some analyses.
MMP‑7 levels correlate in some studies with histologic fibrosis stage and may reflect disease severity, but findings vary and interpretation is assay‑ and cohort‑dependent.

When to use MMP‑7 in clinical practice

Consider serum MMP‑7 as a noninvasive adjunct in the diagnostic pathway for infants with conjugated hyperbilirubinemia when the clinical picture and initial imaging are indeterminate and rapid differentiation between BA and other causes (eg, neonatal hepatitis) is needed.
MMP‑7 is most useful as an early rule‑in/rule‑out aid to prioritize expedited referral to hepatobiliary surgical centers for infants with high likelihood of BA, potentially reducing time to diagnostic cholangiography and Kasai when indicated.
Do not rely on MMP‑7 alone to make a definitive diagnosis; intraoperative cholangiography and histology remain the diagnostic standards. Use MMP‑7 to complement clinical, laboratory, and imaging data and to triage urgency of referral and further testing.

Limitations and practical considerations

Assay variability, differing sample handling protocols, and lack of universally standardized cutoffs limit cross‑study generalizability; each center should validate assays and interpret results in the context of local reference ranges and clinical pathways.
Heterogeneity across studies and patient populations exists; MMP‑7 performs best as part of a structured diagnostic algorithm rather than as a standalone test.
False positives and false negatives occur; combine MMP‑7 with clinical assessment, GGT, ultrasound, HIDA (where available), and consider early biopsy or cholangiography when suspicion remains high despite biomarker results.

Differential diagnosis

Neonatal hepatitis and idiopathic neonatal cholestasis.
Alpha‑1 antitrypsin deficiency, metabolic liver disease, genetic cholestatic disorders, cystic fibrosis, choledochal cyst, inspissated bile, and sepsis.

Treatment

Surgical

Kasai portoenterostomy (hepatoportoenterostomy) is the initial surgical therapy: excision of the fibrotic extrahepatic biliary remnant with a Roux‑en‑Y jejunal conduit to allow bile drainage from microscopic ducts at the porta hepatis.
Timing: earlier surgery is associated with better bile drainage and improved native‑liver survival; centers aim for Kasai by ≈45 days and generally before 60 days when possible — outcomes decline with increasing age at surgery.

Medical and supportive care

Nutrition: aggressive caloric support and optimization of fat absorption; consider medium‑chain triglyceride (MCT) supplementation or MCT‑based formulas; monitor growth and micronutrients.
Fat‑soluble vitamin supplementation (A, D, E, K) and correction of vitamin K deficiency when present.
Ursodeoxycholic acid (UDCA) is commonly used as adjunctive therapy; evidence is limited but practice is widespread.
Pruritus: bile‑acid sequestrants (eg, cholestyramine) and symptomatic agents (eg, antihistamines) as adjuncts.
Antibiotics: treat cholangitis promptly; some centers use post‑Kasai prophylactic antibiotics (practice varies).

Indications for liver transplantation

Failed Kasai (persistent jaundice), progressive liver failure, refractory or recurrent severe cholangitis, portal hypertension complications, or PN‑associated liver disease when present.

Complications and post‑Kasai issues

Cholangitis: common and potentially recurrent; presents with fever, worsening jaundice, acholic stools, irritability; treat promptly with IV antibiotics.
Portal hypertension: progressive fibrosis leading to splenomegaly, hypersplenism, varices, ascites; manage medically and refer for transplant when indicated.
Nutrition and growth failure: ongoing risk despite Kasai; monitor and treat deficiencies.

Prognosis and outcome predictors

Best predictors of improved native‑liver survival: younger age at Kasai, successful clearance of jaundice after Kasai, less portal fibrosis at surgery, and absence of syndromic anomalies.
Many children ultimately require liver transplantation; combined Kasai and transplant strategies have improved long‑term survival into adulthood.

Practical clinical points

Any infant with conjugated hyperbilirubinemia or persistent jaundice beyond 2 weeks requires prompt evaluation: check direct bilirubin, stool color, and refer urgently when BA is suspected.
Use a rapid diagnostic pathway: ultrasound ± HIDA (with standardized protocols), consider serum MMP‑7 as a noninvasive adjunct when available, perform timely liver biopsy if indicated, and proceed to early surgical exploration with intraoperative cholangiography when BA remains likely.
Coordinate care at a pediatric hepatobiliary/transplant center and provide multidisciplinary support (hepatology, surgery/transplant, nutrition, infectious disease, social work).

MMP‑7 testing availability and assays vary by region and laboratory; if you plan to incorporate MMP‑7 into your diagnostic pathway, validate the assay locally, define laboratory cutoffs, and create an algorithm that integrates MMP‑7 with imaging and clinical criteria to avoid delays or inappropriate referrals.

References

Hartley J, Davenport M, Kelly D. Biliary atresia. Lancet. 2009;374(9702):1704–1713.
Lertudomphonwanit C, et al. Large‑scale proteomics identifies MMP‑7 as a sentinel of epithelial injury and of biliary atresia. Sci Transl Med. 2017;9:eaan8462.
Jiang J, Wang J, Shen Z, et al. Serum MMP‑7 in the Diagnosis of Biliary Atresia. Pediatrics. 2019;144(5):e20190902.
Recent systematic reviews and meta‑analyses evaluating serum MMP‑7 diagnostic accuracy for BA (pooled sensitivity and specificity estimates; assay heterogeneity noted) — see pediatric surgery and pharmacology systematic reviews 2024–2025.
AASLD and major pediatric hepatology guidance statements on neonatal cholestasis and biliary atresia; society guidelines and institutional protocols for timing of Kasai and referral pathways.
https://www.naspghan.org/files/documents/pdfs/position-papers/Guideline_for_the_Evaluation_of_Cholestatic.23.pdf